-+ 0.00%
-+ 0.00%
-+ 0.00%

Tempest targets Q4 2026 registrational study start for TPST-2003 CAR-T in myeloma

PUBT·04/22/2026 12:06:04
Listen to the news
Tempest targets Q4 2026 registrational study start for TPST-2003 CAR-T in myeloma
  • Tempest reached a manufacturing milestone for TPST-2003, its dual-targeting CD19/BCMA CAR-T program for relapsed or refractory multiple myeloma.
  • Delivery of lentiviral vector to Cincinnati Children’s Applied Gene and Cell Therapy Center clears work needed to support pivotal development.
  • Tempest is targeting initiation of a potentially registrational study in Q4 2026.
  • Interim clinical results were already disclosed, with future updates slated for presentation at a scientific meeting later in 2026.
  • Across ongoing studies, TPST-2003 has produced deep responses in treated patients, supporting an accelerated development timeline.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief on April 22, 2026, and is solely responsible for the information contained therein.